Norovirus major capsid protein VP1 protruding domain (GII.4) (VP1 P domain (GII.4))

The Norovirus VP1 P domain (GII.4) is the protruding portion of the major capsid protein VP1, specifically from the Genogroup II, genotype 4 strain, which is the predominant cause of human gastroenteritis outbreaks worldwide (PubMed: 23303609). This domain is critical for viral pathogenesis as it contains the binding sites for Histo-Blood Group Antigens (HBGAs), which serve as the primary attachment factors for host cell entry (PubMed: 25122779). Structurally, the P domain is divided into P1 and P2 subdomains, with the P2 subdomain being highly variable and responsible for both receptor interaction and immune recognition (UniProt: Q83884). Because it is the most exposed part of the viral capsid, it is the primary target for neutralizing antibodies and the development of vaccines, such as virus-like particle (VLP) candidates like HIL-214 (ClinicalTrials.gov: NCT03039790). Therapeutic strategies targeting this domain often focus on small-molecule inhibitors or carbohydrate mimics, such as 2'-fucosyllactose, that block the HBGA binding pocket to prevent viral attachment (PubMed: 27117216). However, the rapid evolution and antigenic drift of the GII.4 lineage present significant challenges for long-term vaccine efficacy and drug design.

Other names

Norovirus VP1 P domainGII.4 P domainProtruding domain of VP1Major capsid protein P domainVP1 P2 subdomain

Inhibition of viral attachment to host Histo-Blood Group Antigens (HBGAs) by blocking the receptor-binding site on the P2 subdomain and neutralizing viral entry.